EurekaMag.com logo
+ Site Statistics
References:
47,893,527
Abstracts:
28,296,643
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

4-Hydroxyandrostenedione: A new treatment for postmenopausal patients with breast cancer


, : 4-Hydroxyandrostenedione: A new treatment for postmenopausal patients with breast cancer. European Journal of Cancer 28A(12): 1941-1945

We have evaluated 4-hydroxyandrostenedione, a specific inhibitor of aromatase, as treatment for breast cancer in a phase I dose-ranging study and a phase II study of the best-tolerated dose. 168 postmenopausal patients with locally advanced and metastatic breast cancer were treated intramuscularly. 19% of patients attained a complete or partial response but 26% of those who completed at least 4 weeks treatment responded. Side-effects were least in the group receiving 250 mg every 2 weeks. 13% of patients experienced local discomfort due to the injection and 5% had other side-effects. Serum oestradiol fell to 42.4 and 26.5% of baseline at 7 days after the start of treatment with the 250 mg and 500 mg dose, respectively. We conclude that 4-hydroxyandrostenedione at 250 mg every 2 weeks is a safe and effective form of treatment for postmenopausal patients with metastatic breast cancer.

Accession: 008016584

PMID: 1419285

DOI: 10.1016/0959-8049(92)90232-Q

Download PDF Full Text: 4-Hydroxyandrostenedione: A new treatment for postmenopausal patients with breast cancer


Submit PDF Full Text

No spam - Every submission is manually reviewed

Due to poor quality, we do not accept files from Researchgate

Submitted PDF Full Texts will always be free for everyone
(We only charge for PDFs that we need to acquire)

Select a PDF file:
Close
Close

Related references

Coombes, R.C.; Hughes, S.W.; Dowsett, M., 1992: 4-hydroxyandrostenedione: a new treatment for postmenopausal patients with breast cancer. We have evaluated 4-hydroxyandrostenedione, a specific inhibitor of aromatase, as treatment for breast cancer in a phase I dose-ranging study and a phase II study of the best-tolerated dose. 168 postmenopausal patients with locally advanced and me...

Coombes, R.C., 1992: 4-Hydroxyandrostenedione treatment for postmenopausal patients with breast cancer. Patients (186) with locally advanced or metastatic breast cancer were treated with the aromatase inhibitor 4-hydroxyandrostenedione given parenterally at 3 different doses. 21% of patients responded to treatment, 93% of objective responders whose...

Coombes, R.C.; Goss, P.E.; Dowsett, M.; Hutchinson, G.; Cunningham, D.; Jarman, M.; Brodie, A.M., 1987: 4-Hydroxyandrostenedione treatment for postmenopausal patients with advanced breast cancer. We have treated 128 postmenopausal women with advanced breast cancer with 4-hydroxyandrostenedione. Of these, 118 were assessable for toxicity and 100 for response to treatment. Response to therapy was seen in 34% of patients and stabilization of...

Coombes, R.C.; Goss, P.; Dowsett, M.; Gazet, J.C.; Brodie, A., 1984: 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer. 4-hydroxyandrostenedione, a potent inhibitor of the aromatase (oestrogen synthetase) system, was given to 11 patients with metastatic breast cancer. After a single 500 mg intramuscular injection a sustained reduction of serum oestradiol was observ...

Bajetta E.; Zilembo N.; Buzzoni R.; Mosconi A.; Bartoli C.; Attili A.; Secreto G.; Bichisao E.; Boracchi P., 1990: Treatment of metastatic breast cancer mbc in postmenopausal patients with 4 hydroxyandrostenedione 4 oha cgp 32 349. Journal of Cancer Research & Clinical Oncology 116(SUPPL PART 1): 395

Bajetta, E.; Zilembo, N.; Buzzoni, R.; Noberasco, C.; Celio, L.; Bichisao, E., 1993: Efficacy and tolerability of 4-hydroxyandrostenedione as first-line treatment in postmenopausal patients with breast cancer after adjuvant therapy. Cancer Treatment Reviews 19(SUPPL B): 31-36

Bajetta, E.; Zilembo, N.; Buzzoni, R.; Noberasco, C.; Celio, L.; Bichisao, E., 1993: Efficacy and tolerability of 4-hydroxyandrostenedione (4-OHA) as first-line treatment in postmenopausal patients with breast cancer after adjuvant therapy. Aromatase inhibitors are known to be effective in the treatment of advanced postmenopausal breast cancer. To assess the efficacy of the aromatase inhibitor 4-hydroxyandrostenedione (4-OHA) as first-line treatment in patients who were either resist...

Höffken, K.; Jonat, W.; Possinger, K.; Kölbel, M.; Kunz, T.; Wagner, H.; Becher, R.; Callies, R.; Friederich, P.; Willmanns, W., 1990: Aromatase inhibition with 4-hydroxyandrostenedione in the treatment of postmenopausal patients with advanced breast cancer: a phase II study. Estrogen deprivation by aromatase inhibition is an effective treatment in breast cancer. Between October 1986 and March 1988, 91 postmenopausal patients with advanced breast cancer entered a phase II study performed jointly in three center to inve...

Stein, R.C.; Dowsett, M.; Hedley, A.; Davenport, J.; Gazet, J.C.; Ford, H.T.; Coombes, R.C., 1990: Treatment of advanced breast cancer in postmenopausal women with 4-hydroxyandrostenedione. 4-Hydroxyandrostenedione (4-OHA), a new specific aromatase inhibitor, was used to treat 57 postmenopausal women with advanced breast cancer at a dose of 250 mg by i.m. injection every 2 weeks; 55 women were assessable for response. In all, 18 pati...

Mehta A.; King N.; Dowsett M.; Smith I.E.; Powles T.J.; Coombes R.C., 1989: Endocrine pharmacology of oral 4 hydroxyandrostenedione in postmenopausal breast cancer patients. Journal of Endocrinology 123(SUPPL): 153